THU156 Significantly Improved Annual Height Velocity With Once-Weekly TransCon CNP In Children With Achondroplasia: The ACcomplisH Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Trial

Disclosure: R. Savarirayan: Advisory Board Member; Self; Biomarin, Ascendis. Consulting Fee; Self; BridgeBio. C. McDonnell: Advisory Board Member; Self; Pfizer. Research Investigator; Self; Ascendis, KyowaKirin. Other; Self; Honoraria: Biomarin, Pfizer; Travel, Accommodations, and Expenses: Pfizer....

Descripción completa

Detalles Bibliográficos
Autores principales: Savarirayan, Ravi, McDonnell, Ciara, Hoernschemeyer, Daniel G, Hove, Hanne B, Zarate, Yuri A, Bober, Michael B, Bacino, Carlos A, Legare, Janet M, Högler, Wolfgang, Quattrin, Teresa, Abuzzahab, M Jennifer, Hofman, Paul L, White, Klane K, Ma, Nina, Schnabel, Dirk, Sousa, Sérgio B, Fan, Xiaolin, Chakraborty, Mukta, Giwa, Adebola, Smith, Sharon E, Volck, Birgitte, Shu, Aimee D
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Pediatric Endocrinology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10555328/
http://dx.doi.org/10.1210/jendso/bvad114.1408

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10555328/
http://dx.doi.org/10.1210/jendso/bvad114.1408

Ejemplares similares